Okay_老虎社区_美港股上老虎

2021-11-01

Okay

2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":849836891,"tweetId":"849836891","gmtCreate":1635740774157,"gmtModify":1635740774157,"author":{"id":4094912318336650,"idStr":"4094912318336650","authorId":4094912318336650,"authorIdStr":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Okay&nbsp;</body></html>","htmlText":"<html><head></head><body>Okay&nbsp;</body></html>","text":"Okay","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/849836891","repostId":1164035523,"repostType":4,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohunote.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;Axsome Therapeutics, the cancer specialist&nbsp;Exelixis, and the electric car pioneer&nbsp;Tesla&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.<blockquote>由于科技和医疗保健领域正在进行的创新革命，股东在过去十年中享受了历史性的资本回报。例如，中枢神经系统疾病药物专家Axsome疗法癌症专家埃克塞利西斯以及电动汽车先驱特斯拉都为在这些股票最低点买入的投资者带来了十倍的回报。</blockquote> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.<blockquote>从增长的角度来看，哪些股票可能是下一个 Axsome、Exelixis 或特斯拉？癌症/罕见病专家梅瑞奥生物制药集团（纳斯达克股票代码：MREO）和专注于糖尿病的医疗器械公司Senseonics控股(NYSEMKT:SENS)两者都可能很快就会迎来大幅上涨。事实上，这两只低价医疗保健股票很有可能在未来两到三年内为股东带来 1,000% 以上的回报。</blockquote> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.<blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote> Mereo BioPharma: A bet on the future of immunotherapy<blockquote>Mereo BioPharma：押注免疫疗法的未来</blockquote> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.<blockquote>自从其美国存托股 (ADS) 在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司 Mereo 并没有引起世界的轰动。与这一主题保持一致，自2019年4月以来，生物技术的广告已经损失了约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo 股价暴跌更多的是由于市场先生对临床阶段生物技术公司众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;BeiGene,Bristol Myers Squibb,Merck, and&nbsp;Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.<blockquote>独家新闻是什么？Mereo 是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，毫无疑问，一种可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如百济神州,百时美施贵宝,默克，和罗氏由于抗TIGIT疗法有可能提高癌症免疫治疗的疗效和持久性，因此正在开发抗TIGIT疗法。Mereo 的 etigilimab 目前正在进行一项联合 1/2 期篮子研究，以评估其与 Bristol 的超级重磅检查点抑制剂 Opdivo 一起作为联合治疗的一部分对多种实体瘤的效用。</blockquote> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.<blockquote>就目前情况来看，Mereo 的反 TIGIT 候选人预计将在大约 18 个月后从这项篮子试验中获得顶级数据。然而，在这漫长的间隔期间，该制药商应该提供有关 etigilimab 进展的多项更新，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道，Mereo 的现金跑道将延长至 2024 年。这是关键，因为这意味着生物技术公司不必在未来一年半的时间里反复利用公开市场来获取资金。</blockquote> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.<blockquote>下行风险是什么？Mereo 的管理团队一直公开表示希望与大型生物制药公司合作。就依吉利单抗而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很多人都依赖于这种单一的实验性药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将对生物技术公司的股价造成沉重压力，潜在投资者可能希望将任何初始头寸保持在较小的一侧。</blockquote> Senseonic: A rising tide lifts all boats<blockquote>Senseonic：涨潮举起所有船只</blockquote> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;per year&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.<blockquote>Senseonics 的股票值得极端激进的投资者关注，因为它拥有名为 Eversense 的植入式连续血糖监测 (CGM) 设备特许经营权。内幕是 CGM 市场一直在增长超过 10%每年根据大观研究公司的一份报告，在过去的五年里。更重要的是，预计未来五年，这一领域每年将至少增长10%。对于 Senseonics 这样的小盘船公司来说，这绝对是一个有利的趋势。</blockquote> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.<blockquote>到目前为止，Senseonics 凭借其 Eversense 特许经营权仅占据了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过美国食品药品监督管理局 (FDA) 对其 180 天版本的 Eversense CGM 系统的潜在监管批准来大幅改善其竞争地位。这家医疗器械公司一年多前就该拟议产品向 FDA 提交了监管申请。所以现在随时都可能做出决定。</blockquote> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;DexCom&nbsp;and&nbsp;Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.<blockquote>为什么FDA的批准很重要？Senseonics 的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过 70% 的复合年增长率增长。总而言之，当前的 90 天 Eversense CGM 系统在美国与市场领先的设备相比并不特别具有竞争力德克斯康和雅培实验室，分别。但这种更持久的设备版本可能会导致未来几年的销量飙升。</blockquote> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.<blockquote>有什么风险？Senseonics 正在一个拥挤的领域与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线式增长。这并不是对 Senseonics 的 CGM 系统的打击，而是与拥有极其优势资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在风险因素。</blockquote> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.<blockquote>总而言之，Senseonics 可能正处于一场改变游戏规则的监管事件的边缘，这可能会成为该公司 CGM 特许经营权的一个关键拐点。如果属实，这家医疗器械公司的股票在这些水平上应该会变得非常便宜。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-11-01 11:14\n\n</h4>\n</header>\n<article>\nThanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;Axsome Therapeutics, the cancer specialist&nbsp;Exelixis, and the electric car pioneer&nbsp;Tesla&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.<blockquote>由于科技和医疗保健领域正在进行的创新革命，股东在过去十年中享受了历史性的资本回报。例如，中枢神经系统疾病药物专家Axsome疗法癌症专家埃克塞利西斯以及电动汽车先驱特斯拉都为在这些股票最低点买入的投资者带来了十倍的回报。</blockquote> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.<blockquote>从增长的角度来看，哪些股票可能是下一个 Axsome、Exelixis 或特斯拉？癌症/罕见病专家梅瑞奥生物制药集团（纳斯达克股票代码：MREO）和专注于糖尿病的医疗器械公司Senseonics控股(NYSEMKT:SENS)两者都可能很快就会迎来大幅上涨。事实上，这两只低价医疗保健股票很有可能在未来两到三年内为股东带来 1,000% 以上的回报。</blockquote> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.<blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote> Mereo BioPharma: A bet on the future of immunotherapy<blockquote>Mereo BioPharma：押注免疫疗法的未来</blockquote> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.<blockquote>自从其美国存托股 (ADS) 在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司 Mereo 并没有引起世界的轰动。与这一主题保持一致，自2019年4月以来，生物技术的广告已经损失了约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo 股价暴跌更多的是由于市场先生对临床阶段生物技术公司众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;BeiGene,Bristol Myers Squibb,Merck, and&nbsp;Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.<blockquote>独家新闻是什么？Mereo 是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，毫无疑问，一种可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如百济神州,百时美施贵宝,默克，和罗氏由于抗TIGIT疗法有可能提高癌症免疫治疗的疗效和持久性，因此正在开发抗TIGIT疗法。Mereo 的 etigilimab 目前正在进行一项联合 1/2 期篮子研究，以评估其与 Bristol 的超级重磅检查点抑制剂 Opdivo 一起作为联合治疗的一部分对多种实体瘤的效用。</blockquote> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.<blockquote>就目前情况来看，Mereo 的反 TIGIT 候选人预计将在大约 18 个月后从这项篮子试验中获得顶级数据。然而，在这漫长的间隔期间，该制药商应该提供有关 etigilimab 进展的多项更新，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道，Mereo 的现金跑道将延长至 2024 年。这是关键，因为这意味着生物技术公司不必在未来一年半的时间里反复利用公开市场来获取资金。</blockquote> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.<blockquote>下行风险是什么？Mereo 的管理团队一直公开表示希望与大型生物制药公司合作。就依吉利单抗而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很多人都依赖于这种单一的实验性药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将对生物技术公司的股价造成沉重压力，潜在投资者可能希望将任何初始头寸保持在较小的一侧。</blockquote> Senseonic: A rising tide lifts all boats<blockquote>Senseonic：涨潮举起所有船只</blockquote> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;per year&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.<blockquote>Senseonics 的股票值得极端激进的投资者关注，因为它拥有名为 Eversense 的植入式连续血糖监测 (CGM) 设备特许经营权。内幕是 CGM 市场一直在增长超过 10%每年根据大观研究公司的一份报告，在过去的五年里。更重要的是，预计未来五年，这一领域每年将至少增长10%。对于 Senseonics 这样的小盘船公司来说，这绝对是一个有利的趋势。</blockquote> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.<blockquote>到目前为止，Senseonics 凭借其 Eversense 特许经营权仅占据了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过美国食品药品监督管理局 (FDA) 对其 180 天版本的 Eversense CGM 系统的潜在监管批准来大幅改善其竞争地位。这家医疗器械公司一年多前就该拟议产品向 FDA 提交了监管申请。所以现在随时都可能做出决定。</blockquote> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;DexCom&nbsp;and&nbsp;Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.<blockquote>为什么FDA的批准很重要？Senseonics 的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过 70% 的复合年增长率增长。总而言之，当前的 90 天 Eversense CGM 系统在美国与市场领先的设备相比并不特别具有竞争力德克斯康和雅培实验室，分别。但这种更持久的设备版本可能会导致未来几年的销量飙升。</blockquote> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.<blockquote>有什么风险？Senseonics 正在一个拥挤的领域与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线式增长。这并不是对 Senseonics 的 CGM 系统的打击，而是与拥有极其优势资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在风险因素。</blockquote> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.<blockquote>总而言之，Senseonics 可能正处于一场改变游戏规则的监管事件的边缘，这可能会成为该公司 CGM 特许经营权的一个关键拐点。如果属实，这家医疗器械公司的股票在这些水平上应该会变得非常便宜。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SENS":"Senseonics Holdings,Inc.","MREO":"Mereo Biopharma Group Plc"},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"SENS":0.9,"MREO":0.9}},"isVote":1,"tweetType":1,"viewCount":1979,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/849836891"}